4D Molecular Therapeutics, Inc.
FDMT
$6.12
-$0.06-0.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.00K | 23.00K | 37.00K | 17.00K | 20.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.00K | 23.00K | 37.00K | 17.00K | 20.22M |
| Cost of Revenue | 170.22M | 154.13M | 141.30M | 124.24M | 110.82M |
| Gross Profit | -170.19M | -154.11M | -141.26M | -124.23M | -90.61M |
| SG&A Expenses | 50.14M | 49.22M | 46.58M | 44.15M | 40.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 220.36M | 203.35M | 187.88M | 168.39M | 151.44M |
| Operating Income | -220.33M | -203.33M | -187.84M | -168.38M | -131.22M |
| Income Before Tax | -196.14M | -176.44M | -160.87M | -143.48M | -109.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -196.14 | -176.44 | -160.87 | -143.48 | -109.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -196.14M | -176.44M | -160.87M | -143.48M | -109.89M |
| EBIT | -220.33M | -203.33M | -187.84M | -168.38M | -131.22M |
| EBITDA | -215.82M | -198.80M | -183.19M | -163.72M | -126.76M |
| EPS Basic | -3.52 | -3.17 | -2.97 | -2.83 | -2.29 |
| Normalized Basic EPS | -2.20 | -1.98 | -1.86 | -1.77 | -1.43 |
| EPS Diluted | -3.52 | -3.17 | -2.97 | -2.83 | -2.29 |
| Normalized Diluted EPS | -2.20 | -1.98 | -1.86 | -1.77 | -1.43 |
| Average Basic Shares Outstanding | 222.87M | 222.22M | 215.75M | 202.98M | 189.68M |
| Average Diluted Shares Outstanding | 222.87M | 222.22M | 215.75M | 202.98M | 189.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |